Payam Mohassel1, Ning Chang1, Kaoru Inoue1, Angela Delaney1, Ying Hu1, Sandra Donkervoort1, Dimah Saade1, B Jeanne Billioux1, Brooke Meader1, Rita Volochayev1, Chamindra G Konersman1, Angela M Kaindl1, Chie-Hee Cho1, Bianca Russell1, Adrian Rodriguez1, K Wade Foster1, A Reghan Foley1, Steven A Moore1, Peter L Jones1, Carsten G Bonnemann1, Takako Jones1, Natalie D Shaw2. 1. From the Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch (P.M., Y.H., S.D., D.S., A.R.F., C.G.B.), and International Neuroinfectious Diseases Unit, Division of Neuroimmunology and Neurovirology (B.J.B.), National Institute of Neurological Disorders and Stroke, National Institute of Child Health and Development (A.D., B.M.), and Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (R.V.), National Institutes of Health, Bethesda, MD; Department of Pharmacology (N.C., P.L.J., T.J.), Reno School of Medicine, University of Nevada; Pediatric Neuroendocrinology Group, Clinical Research Branch, National Institute of Environmental Health Sciences (K.I., N.D.S.), National Institutes of Health, Research Triangle Park, NC; Department of Neurosciences (C.G.K.), University of California, San Diego; Department of Pediatric Neurology, Center for Chronically Sick Children and Institute of Cell Biology and Neurobiology (A.M.K.), Charitè-Universitätsmedizin Berlin, Germany; Institute for Diagnostic and Interventional Radiology (C.-H.C.), University Clinic, Jena, Germany; Division of Pediatric Genetics, Department of Pediatrics (B.R.), University of California, Los Angeles; Nashville Skin and Cancer (A.R.), TN; Florida Dermatology and Skin Cancer Centers (K.W.F.), Winter Haven; and Department of Pathology, University of Iowa Carver College of Medicine (S.A.M.), Iowa City. 2. From the Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch (P.M., Y.H., S.D., D.S., A.R.F., C.G.B.), and International Neuroinfectious Diseases Unit, Division of Neuroimmunology and Neurovirology (B.J.B.), National Institute of Neurological Disorders and Stroke, National Institute of Child Health and Development (A.D., B.M.), and Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (R.V.), National Institutes of Health, Bethesda, MD; Department of Pharmacology (N.C., P.L.J., T.J.), Reno School of Medicine, University of Nevada; Pediatric Neuroendocrinology Group, Clinical Research Branch, National Institute of Environmental Health Sciences (K.I., N.D.S.), National Institutes of Health, Research Triangle Park, NC; Department of Neurosciences (C.G.K.), University of California, San Diego; Department of Pediatric Neurology, Center for Chronically Sick Children and Institute of Cell Biology and Neurobiology (A.M.K.), Charitè-Universitätsmedizin Berlin, Germany; Institute for Diagnostic and Interventional Radiology (C.-H.C.), University Clinic, Jena, Germany; Division of Pediatric Genetics, Department of Pediatrics (B.R.), University of California, Los Angeles; Nashville Skin and Cancer (A.R.), TN; Florida Dermatology and Skin Cancer Centers (K.W.F.), Winter Haven; and Department of Pathology, University of Iowa Carver College of Medicine (S.A.M.), Iowa City. natalie.shaw@nih.gov.
Abstract
BACKGROUND AND OBJECTIVES: Facioscapulohumeral muscular dystrophy type 2 (FSHD2) and arhinia are 2 distinct disorders caused by pathogenic variants in the same gene: SMCHD1. The mechanism underlying this phenotypic divergence remains unclear. In this study, we characterize the neuromuscular phenotype of individuals with arhinia caused by SMCHD1 variants and analyze their complex genetic and epigenetic criteria to assess their risk for FSHD2. METHODS: Eleven individuals with congenital nasal anomalies, including arhinia, nasal hypoplasia, or anosmia, underwent a neuromuscular examination, genetic testing, muscle ultrasound, and muscle MRI. Risk for FSHD2 was determined by combined genetic and epigenetic analysis of 4q35 haplotype, D4Z4 repeat length, and methylation profile. We also compared expression levels of pathogenic DUX4 mRNA in primary myoblasts or dermal fibroblasts (upon myogenic differentiation or epigenetic transdifferentiation, respectively) in these individuals vs those with confirmed FSHD2. RESULTS: Among the 11 individuals with rare, pathogenic, heterozygous missense variants in exons 3-11 of SMCHD1, only a subset (n = 3/11; 1 male, 2 female; age 25-51 years) met the strict genetic and epigenetic criteria for FSHD2 (D4Z4 repeat unit length <21 in cis with a 4qA haplotype and D4Z4 methylation <30%). None of the 3 individuals had typical clinical manifestations or muscle imaging findings consistent with FSHD2. However, the patients with arhinia meeting the permissive genetic and epigenetic criteria for FSHD2 displayed some DUX4 expression in dermal fibroblasts under the epigenetic de-repression by drug treatment and in the primary myoblasts undergoing myogenic differentiation. DISCUSSION: In this cross-sectional study, we identified patients with arhinia who meet the full genetic and epigenetic criteria for FSHD2 and display the molecular hallmark of FSHD-DUX4 de-repression and expression in vitro-but who do not manifest with the typical clinicopathologic phenotype of FSHD2. The distinct dichotomy between FSHD2 and arhinia phenotypes despite an otherwise poised DUX4 locus implies the presence of novel disease-modifying factors that seem to operate as a switch, resulting in one phenotype and not the other. Identification and further understanding of these disease-modifying factors will provide valuable insight with therapeutic implications for both diseases. Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
BACKGROUND AND OBJECTIVES: Facioscapulohumeral muscular dystrophy type 2 (FSHD2) and arhinia are 2 distinct disorders caused by pathogenic variants in the same gene: SMCHD1. The mechanism underlying this phenotypic divergence remains unclear. In this study, we characterize the neuromuscular phenotype of individuals with arhinia caused by SMCHD1 variants and analyze their complex genetic and epigenetic criteria to assess their risk for FSHD2. METHODS: Eleven individuals with congenital nasal anomalies, including arhinia, nasal hypoplasia, or anosmia, underwent a neuromuscular examination, genetic testing, muscle ultrasound, and muscle MRI. Risk for FSHD2 was determined by combined genetic and epigenetic analysis of 4q35 haplotype, D4Z4 repeat length, and methylation profile. We also compared expression levels of pathogenic DUX4 mRNA in primary myoblasts or dermal fibroblasts (upon myogenic differentiation or epigenetic transdifferentiation, respectively) in these individuals vs those with confirmed FSHD2. RESULTS: Among the 11 individuals with rare, pathogenic, heterozygous missense variants in exons 3-11 of SMCHD1, only a subset (n = 3/11; 1 male, 2 female; age 25-51 years) met the strict genetic and epigenetic criteria for FSHD2 (D4Z4 repeat unit length <21 in cis with a 4qA haplotype and D4Z4 methylation <30%). None of the 3 individuals had typical clinical manifestations or muscle imaging findings consistent with FSHD2. However, the patients with arhinia meeting the permissive genetic and epigenetic criteria for FSHD2 displayed some DUX4 expression in dermal fibroblasts under the epigenetic de-repression by drug treatment and in the primary myoblasts undergoing myogenic differentiation. DISCUSSION: In this cross-sectional study, we identified patients with arhinia who meet the full genetic and epigenetic criteria for FSHD2 and display the molecular hallmark of FSHD-DUX4 de-repression and expression in vitro-but who do not manifest with the typical clinicopathologic phenotype of FSHD2. The distinct dichotomy between FSHD2 and arhinia phenotypes despite an otherwise poised DUX4 locus implies the presence of novel disease-modifying factors that seem to operate as a switch, resulting in one phenotype and not the other. Identification and further understanding of these disease-modifying factors will provide valuable insight with therapeutic implications for both diseases. Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Authors: Richard J L F Lemmers; Patrick J van der Vliet; Rinse Klooster; Sabrina Sacconi; Pilar Camaño; Johannes G Dauwerse; Lauren Snider; Kirsten R Straasheijm; Gert Jan van Ommen; George W Padberg; Daniel G Miller; Stephen J Tapscott; Rabi Tawil; Rune R Frants; Silvère M van der Maarel Journal: Science Date: 2010-08-19 Impact factor: 47.728
Authors: Richard J L F Lemmers; Patrick J van der Vliet; Kristiaan J van der Gaag; Sofia Zuniga; Rune R Frants; Peter de Knijff; Silvère M van der Maarel Journal: Am J Hum Genet Date: 2010-03-04 Impact factor: 11.025
Authors: Natalie D Shaw; Harrison Brand; Zachary A Kupchinsky; Hemant Bengani; Lacey Plummer; Takako I Jones; Serkan Erdin; Kathleen A Williamson; Joe Rainger; Alexei Stortchevoi; Kaitlin Samocha; Benjamin B Currall; Donncha S Dunican; Ryan L Collins; Jason R Willer; Angela Lek; Monkol Lek; Malik Nassan; Shahrin Pereira; Tammy Kammin; Diane Lucente; Alexandra Silva; Catarina M Seabra; Colby Chiang; Yu An; Morad Ansari; Jacqueline K Rainger; Shelagh Joss; Jill Clayton Smith; Margaret F Lippincott; Sylvia S Singh; Nirav Patel; Jenny W Jing; Jennifer R Law; Nalton Ferraro; Alain Verloes; Anita Rauch; Katharina Steindl; Markus Zweier; Ianina Scheer; Daisuke Sato; Nobuhiko Okamoto; Christina Jacobsen; Jeanie Tryggestad; Steven Chernausek; Lisa A Schimmenti; Benjamin Brasseur; Claudia Cesaretti; Jose E García-Ortiz; Tatiana Pineda Buitrago; Orlando Perez Silva; Jodi D Hoffman; Wolfgang Mühlbauer; Klaus W Ruprecht; Bart L Loeys; Masato Shino; Angela M Kaindl; Chie-Hee Cho; Cynthia C Morton; Richard R Meehan; Veronica van Heyningen; Eric C Liao; Ravikumar Balasubramanian; Janet E Hall; Stephanie B Seminara; Daniel Macarthur; Steven A Moore; Koh-Ichiro Yoshiura; James F Gusella; Joseph A Marsh; John M Graham; Angela E Lin; Nicholas Katsanis; Peter L Jones; William F Crowley; Erica E Davis; David R FitzPatrick; Michael E Talkowski Journal: Nat Genet Date: 2017-01-09 Impact factor: 38.330
Authors: Lauren Snider; Linda N Geng; Richard J L F Lemmers; Michael Kyba; Carol B Ware; Angelique M Nelson; Rabi Tawil; Galina N Filippova; Silvère M van der Maarel; Stephen J Tapscott; Daniel G Miller Journal: PLoS Genet Date: 2010-10-28 Impact factor: 5.917